Vertex Pharmaceuticals Incorporated will acquire the privately held stem cell therapy developer ViaCyte, Inc. for $320m in cash to expand its pipeline and development flexibility in type 1 diabetes, the company announced on 11 July. ViaCyte's portfolio will complement Vertex's internal effort to develop its allogeneic stem cell-derived, insulin-producing islet cell therapy, VX-880, and bring a functional cure for type 1 diabetes to market, according to Vertex.
Vertex Builds Type 1 Diabetes Reach And Flexibility With ViaCyte
Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.
